The backlash against bioequivalence and the interchangeability of brand-name and generic drugs
Open Access
- 11 July 2011
- journal article
- editorial
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 183 (12), 1350-1351
- https://doi.org/10.1503/cmaj.110808
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Amiodarone-induced thyroid dysfunction: brand-name versus generic formulationsCMAJ : Canadian Medical Association Journal, 2011
- The Consequences of Requesting “Dispense as Written”American Journal Of Medicine, 2011
- Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugsCurrent Medical Research and Opinion, 2009
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 2009
- The risks and costs of multiple-generic substitution of topiramateNeurology, 2009
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- The Implications of ChoiceArchives of Internal Medicine, 2006
- Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmiasThe American Journal of Cardiology, 2000